Portfolio at a glance
Securities as at June 30, 2021
|
Company |
|
Number of securities |
|
Change since 31.12.2020 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Moderna |
|
2 450 000 |
|
(404 963) |
|
USD |
|
234.98 |
|
532.5 |
|
12.2% |
|
13.2% |
|
0.6% |
|
Ionis Pharmaceuticals |
|
9 112 973 |
|
892 973 |
|
USD |
|
39.89 |
|
336.3 |
|
7.7% |
|
8.3% |
|
6.5% |
|
Argenx SE |
|
955 538 |
|
34 206 |
|
USD |
|
301.07 |
|
266.1 |
|
6.1% |
|
6.6% |
|
1.9% |
|
Neurocrine Biosciences |
|
2 915 400 |
|
(119 600) |
|
USD |
|
97.32 |
|
262.4 |
|
6.0% |
|
6.5% |
|
3.1% |
|
Incyte |
|
2 897 000 |
|
(3 000) |
|
USD |
|
84.13 |
|
225.4 |
|
5.2% |
|
5.6% |
|
1.3% |
|
Agios Pharmaceuticals |
|
4 304 992 |
|
146 090 |
|
USD |
|
55.11 |
|
219.5 |
|
5.0% |
|
5.4% |
|
7.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fate Therapeutics |
|
2 546 336 |
|
516 336 |
|
USD |
|
86.79 |
|
204.4 |
|
4.7% |
|
5.1% |
|
2.7% |
|
Vertex Pharmaceuticals |
|
1 050 000 |
|
150 000 |
|
USD |
|
201.63 |
|
195.8 |
|
4.5% |
|
4.8% |
|
0.4% |
|
Alnylam Pharmaceuticals |
|
1 110 000 |
|
(45 000) |
|
USD |
|
169.52 |
|
174.1 |
|
4.0% |
|
4.3% |
|
0.9% |
|
Biogen |
|
500 000 |
|
(37 000) |
|
USD |
|
346.27 |
|
160.1 |
|
3.7% |
|
4.0% |
|
0.3% |
|
Macrogenics |
|
6 275 564 |
|
1 460 000 |
|
USD |
|
26.86 |
|
155.9 |
|
3.6% |
|
3.9% |
|
10.5% |
|
Arvinas |
|
2 176 903 |
|
– |
|
USD |
|
77.00 |
|
155.0 |
|
3.6% |
|
3.8% |
|
4.4% |
|
Crispr Therapeutics |
|
949 584 |
|
48 700 |
|
USD |
|
161.89 |
|
142.2 |
|
3.3% |
|
3.5% |
|
1.3% |
|
Intra-Cellular Therapies |
|
3 488 419 |
|
(50 000) |
|
USD |
|
40.82 |
|
131.7 |
|
3.0% |
|
3.3% |
|
4.3% |
|
Radius Health |
|
7 455 714 |
|
– |
|
USD |
|
18.24 |
|
125.8 |
|
2.9% |
|
3.1% |
|
15.8% |
|
Sage Therapeutics |
|
2 325 104 |
|
785 000 |
|
USD |
|
56.81 |
|
122.2 |
|
2.8% |
|
3.0% |
|
4.0% |
|
Myovant Sciences |
|
5 222 039 |
|
465 000 |
|
USD |
|
22.77 |
|
110.0 |
|
2.5% |
|
2.7% |
|
5.7% |
|
Relay Therapeutics |
|
2 620 962 |
|
1 211 605 |
|
USD |
|
36.59 |
|
88.7 |
|
2.0% |
|
2.2% |
|
2.8% |
|
Esperion Therapeutics |
|
4 477 964 |
|
530 000 |
|
USD |
|
21.15 |
|
87.6 |
|
2.0% |
|
2.2% |
|
15.9% |
|
Beam Therapeutics |
|
606 821 |
|
210 000 |
|
USD |
|
128.71 |
|
72.2 |
|
1.7% |
|
1.8% |
|
1.0% |
|
Molecular Templates |
|
9 542 621 |
|
3 162 290 |
|
USD |
|
7.82 |
|
69.0 |
|
1.6% |
|
1.7% |
|
17.0% |
|
Essa Pharma |
|
2 440 814 |
|
2 440 814 |
|
USD |
|
28.57 |
|
64.5 |
|
1.5% |
|
1.6% |
|
6.0% |
|
Generation Bio Co. |
|
2 453 180 |
|
120 000 |
|
USD |
|
26.90 |
|
61.0 |
|
1.4% |
|
1.5% |
|
4.3% |
|
Scholar Rock Holding |
|
2 275 125 |
|
19 474 |
|
USD |
|
28.90 |
|
60.8 |
|
1.4% |
|
1.5% |
|
6.6% |
|
Halozyme Therapeutics |
|
1 331 966 |
|
(2 638 034) |
|
USD |
|
45.41 |
|
55.9 |
|
1.3% |
|
1.4% |
|
0.9% |
|
Revolution Medicines |
|
1 805 105 |
|
1 805 105 |
|
USD |
|
31.74 |
|
53.0 |
|
1.2% |
|
1.3% |
|
2.5% |
|
Exelixis |
|
2 835 000 |
|
– |
|
USD |
|
18.22 |
|
47.8 |
|
1.1% |
|
1.2% |
|
0.9% |
|
Nektar Therapeutics |
|
2 620 676 |
|
– |
|
USD |
|
17.16 |
|
41.6 |
|
1.0% |
|
1.0% |
|
1.4% |
|
Black Diamond Therapeutics |
|
3 440 000 |
|
2 050 000 |
|
USD |
|
12.19 |
|
38.8 |
|
0.9% |
|
1.0% |
|
9.5% |
|
Mersana Therapeutics |
|
2 860 000 |
|
975 000 |
|
USD |
|
13.58 |
|
35.9 |
|
0.8% |
|
0.9% |
|
4.1% |
|
Kezar Life Sciences |
|
4 533 148 |
|
– |
|
USD |
|
5.43 |
|
22.8 |
|
0.5% |
|
0.6% |
|
9.4% |
|
Wave Life Sciences |
|
2 602 858 |
|
– |
|
USD |
|
6.66 |
|
16.0 |
|
0.4% |
|
0.4% |
|
5.2% |
|
Homology Medicines |
|
1 737 122 |
|
– |
|
USD |
|
7.27 |
|
11.7 |
|
0.3% |
|
0.3% |
|
3.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alder Biopharmaceuticals – Contingent Value Right |
|
2 766 008 |
|
– |
|
USD |
|
0.88 |
|
2.3 |
|
0.1% |
|
0.1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
4 349.3 |
|
100.0% |
|
107.5% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
7.8 |
|
|
|
0.2% |
|
|
|
Other liabilities |
|
|
|
|
|
|
|
|
|
(310.1) |
|
|
|
(7.7%) |
|
|
|
Net asset value |
|
|
|
|
|
|
|
|
|
4 047.0 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BB Biotech registered shares 1) |
|
– |
|
(114 662) |
|
|
|
|
|
|
|
|
|
|
|
|
1 Correspond to the total of all own shares held including the second trading line
Exchange rate as at 30.06.2021: USD/CHF: 0.9250